Inovio gets additional patent for electroporation technology platform

By E. Janene Geiss

Philadelphia, Sept. 6 - Inovio Biomedical Corp. said Wednesday that it received an additional patent from the European Patent Office, further expanding its electroporation technology platform.

This patent (EP1023107) enhances the San Diego company's intellectual property portfolio for electroporation in Europe with claims related to the delivery of DNA-based therapeutics into muscle, the preferred tissue for extended production of antigens and other bioactive agents integral to gene therapy and DNA vaccination, according to a news release.

The patent includes claims covering the most desirable pulsing- and agent-delivery conditions using electroporation to deliver genes and drugs to a variety of tissues.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.